RxDoctor Payments DataLook up a doctor →

Sabarish Ayyappan, MD

Hematology · Iowa City, IANPI 1558551507

Payments from drug & device makers

$2,124,808in general payments, 2019–2025

Across 303 payments — averaging $7012.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$924K
  • Regeneron$418K
  • Gilead$206K
  • Genmab U.S., Inc.$181K
  • Novartis$93K
  • Beone Medicines Ltd.$79K
  • plus $224K from 27 others
$16,785in research payments, 2019–2025

Across 33 payments — averaging $508.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$17K

What the payments were for

  • Consulting fees$75,73053%
  • Speaking & faculty fees$44,35031%
  • Travel & lodging$15,19311%
  • Food & beverage$6,8535%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$52,562
Medicare patients
125
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide74$974,142
CalquenceAcalabrutinib Maleate47$685,957
BrukinsaZanubrutinib33$487,006
PomalystPomalidomide11$275,766
TasignaNilotinib Hcl17$233,722
VenclextaVenetoclax15$149,935
Acyclovir97$838
Dexamethasone25$256
Hydroxyurea19$231
Prochlorperazine Maleate12$196
Pantoprazole Sodium28$190
Allopurinol32$101
Potassium Chloride14$96
Prednisone30$83
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$23,695$685,95747 claims
Beigene USA, Inc.Brukinsa$19,466$487,00633 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$8,012$275,76611 claims
NovartisTasigna$92,912$233,72217 claims
AbbVieVenclexta$23,977$149,93515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other hematology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →